Skip to main content
    A

    Akero Therapeutics Inc (AKRO)

    Official site

    BIOTECHNOLOGY

    $54.65
    +0.00 (+0.00%)

    Last updated: Dec 09, 2025 at 4:00 PM ET

    Akero Therapeutics Inc (AKRO) Financials: Revenue, Profit and Cash Flow

    Updated Nov 7, 2025. Financial statements from company filings, amounts in US dollars.

    Akero Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024. That year, net income was -$252.06M, operating cash flow was -$230.11M and free cash flow was -$231.11M. The quarter ended Sep 30, 2025 had revenue of $0 and net income of -$81.57M.

    Revenue and Margins

    The company reported no revenue in the fiscal year ended Dec 2024, with an operating loss of $285.42M.

    Fiscal yearRevenueGrowthGross marginOperating marginNet margin
    Dec 2024$0N/AN/AN/AN/A
    Dec 2023$0N/AN/AN/AN/A
    Dec 2022$0N/AN/AN/AN/A
    Dec 2021$0N/AN/AN/AN/A
    Dec 2020$0N/AN/AN/AN/A
    Dec 2019$0N/AN/AN/AN/A
    Dec 2018$0N/AN/AN/AN/A
    Dec 2017$0N/AN/AN/AN/A
    Annual, fiscal years ended Dec 2017 to Dec 2024

    Income Statement

    In the fiscal year ended Dec 2024, the net loss widened from the year before. In the quarter ended Sep 2025, the net loss widened from the same quarter a year earlier.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Research and development$247.50M$141.80M$85.28M$81.76M$64.92M$37.05M$11.88M$3.49M
    Operating income-$285.42M-$172.87M-$115.16M-$100.89M-$80.15M-$45.65M-$13.78M-$4.56M
    Net income-$252.06M-$151.76M-$112.03M-$100.78M-$79.21M-$43.76M-$81.71M-$4.56M
    EBITDAN/AN/A-$114.92M-$99.78M-$79.11M-$43.86MN/A-$232.36K
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Revenue$0$0$0$4.00K$0$0$0$284.00K$0$0$0$0
    Gross profit$0$0$0$2.00K$0$0$0-$2.00K$0$0$0-$65.00K
    Operating income-$90.24M-$80.87M-$80.88M-$78.03M-$81.70M-$65.74M-$59.95M-$61.87M-$46.62M-$35.63M-$28.75M-$25.42M
    Net income-$81.57M-$70.50M-$70.72M-$70.02M-$72.70M-$55.99M-$53.34M-$55.19M-$39.66M-$31.08M-$25.83M-$23.06M
    Last 12 quarters

    Balance Sheet

    As of Dec 2024, cash and equivalents exceeded total debt of $35.93M by $304.31M.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Total assets$825.89M$580.27M$356.57M$195.55M$273.34M$138.12M$77.15M$77.15M
    Current assets$770.38M$559.96M$355.17M$193.58M$271.35M$138.05M$77.13M$77.13M
    Cash and equivalents$340.24M$234.21M$249.77M$150.48M$187.24M$64.79M$75.97M$75.97M
    Total liabilities$75.77M$44.97M$30.01M$26.44M$14.63M$9.39M$2.34M$2.34M
    Short-term debt$631.00K$522.00K$325.00K$205.00K$294.00K$85.00K$0$0
    Long-term debt$35.30M$24.96M$9.54M$0N/AN/A$0$0
    Shareholder equity$750.11M$535.31M$326.56M$169.11M$258.71M$128.73M-$49.92M-$49.92M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Total assets$1.01B$1.11B$1.16B$825.89M$817.55M$865.04M$912.24M$580.27M$635.33M$663.81M$348.82M$356.57M
    Total liabilities$47.94M$83.33M$72.00M$75.77M$79.22M$66.98M$65.99M$44.97M$52.20M$47.37M$42.47M$30.01M
    Cash and equivalents$176.03M$220.45M$185.92M$340.24M$316.06M$310.36M$623.85M$234.21M$269.55M$444.16M$257.88M$249.77M
    Shareholder equity$957.64M$1.03B$1.08B$750.11M$738.33M$798.07M$846.25M$535.31M$583.13M$616.44M$306.35M$326.56M
    Last 12 quarters

    Cash Flow

    Operating cash flow was negative in the fiscal year ended Dec 2024.

    Annual

    Line itemDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018Dec 2017
    Operating cash flow-$230.11M-$145.37M-$92.52M-$79.68M-$70.80M-$35.63M-$4.63M-$4.38M
    Capital expenditures$999.00K$0$0$0$148.00K$0$5.00M$148.00K
    Free cash flow-$231.11M-$145.37M-$92.52M-$79.68M-$70.95M-$35.63M-$9.63M-$4.53M
    Dividends paidN/A$229.10MN/AN/AN/AN/A$0$0
    Share repurchases$844.00K$776.00K$864.00K$521.00K$0$0N/AN/A
    Investing cash flow-$109.71M-$223.62M-$63.83M$42.28M-$9.76M-$71.51M-$5.00M-$5.00M
    Financing cash flow$445.85M$353.32M$255.63M$602.00K$203.11M$95.99M$85.01M$5.00M
    Fiscal years ended Dec 2017 to Dec 2024

    Quarterly

    Line itemSep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023Dec 2022
    Operating cash flow-$67.17M-$48.25M-$67.66M-$67.09M-$70.42M-$57.45M-$35.14M-$48.63M-$49.72M-$22.39M-$24.63M-$25.51M
    Capital expenditures$0$0$0$0$0$999.00K$0$0$0$0$0$0
    Free cash flow-$67.17M-$48.25M-$67.66M-$67.09M-$70.42M-$58.45M-$35.14M-$48.63M-$49.72M-$22.39M-$24.63M-$25.51M
    Last 12 quarters

    Frequently Asked Questions About AKRO

    What is Akero Therapeutics' annual revenue?

    Akero Therapeutics reported revenue of $0 for the fiscal year ended Dec 31, 2024.

    Is Akero Therapeutics profitable?

    No. Akero Therapeutics reported net income of -$252.06M for the fiscal year ended Dec 31, 2024.

    How much free cash flow does AKRO generate?

    For the fiscal year ended Dec 31, 2024, operating cash flow of -$230.11M minus capital expenditures of $999.00K produced free cash flow of -$231.11M.

    How much debt does Akero Therapeutics have?

    The balance sheet dated Dec 31, 2024 reported long-term debt of $35.30M, short-term debt of $631.00K and cash and equivalents of $340.24M.